# Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

> **NCT03977233** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Cancer of Pancreas
- Pancreatic Cancer, Adult
- Pancreas Adenocarcinoma
- Pancreatic Neoplasms
- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT03977233
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-12
- **Primary completion:** 2027-07
- **Final completion:** 2030-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977233, "Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03977233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*